At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Rosuvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 26-week, Single Center, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Effect of Rosuvastatin on Visceral Adipose Tissue in Male Patients With Abdominal Obesity
In Brief
A Phase 3 clinical trial evaluating Rosuvastatin and Placebo for rosuvastatin for Abdominal Obesity. Completed, enrolled 54 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbdominal Obesity
CountriesSweden
CollaboratorsSahlgrenska University Hospital
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
Primary CompletionOct 2008
Study CompletionDec 2008
First PostedFeb 2010
TodayJul 2026
First PostedFeb 15, 2010
Enrollment StartMay 1, 2006
Primary CompletionOct 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.4 years ago
Interventions
Rosuvastatindrug
10 mg once daily
Placebo for rosuvastatindrug
once daily